New Facility Helps Scientists Advance Translational Medical Research
WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the opening of the Translational Medical Engineering Demonstration Laboratory at a ceremony on September 19. Co-founded with the State Key Laboratory of Biochemical Engineering, this facility will serve as a center for research and insights related to translational medicine for scientists throughout China.
WHY: A wide range of professionals from scientific institutions, pharmaceutical companies and hospitals will leverage this lab to help advance translational medicine research. They will utilize a wide range of PerkinElmer’s technologies and services across molecular, cellular and small animal imaging.
The lab includes an extensive variety of PerkinElmer’s instrumentation and software. Their applications span vivo imaging, high content screening, quantitative pathology, and multi-mode detection. These technologies include: the Vectra® Polaris™ automated quantitative pathology imaging system the Opera Phenix™ and Operetta CLS™ high content screening system, the IVIS® Spectrum in vivo imaging system, the Quantum GX microCT Imaging System, and the EnVision™ multilabel plate reader.
PerkinElmer and the State Key Laboratory of Biochemical Engineering are also staffing the lab with dedicated professionals responsible for the lab’s daily operation and projects development to ensure that it runs smoothly and efficiently.
“Translational medicine emphasizes the application of the results of basic research to clinical practice, and we are pleased to collaborate with State Key Laboratory of Biochemical Engineering in opening this sophisticated facility,” said Nam-Hoon Kim, President, Discovery & Analytical Solutions, Asia-Pacific, PerkinElmer. “We anticipate that our scientific and business partners will enjoy an excellent customer experience from this new lab.”
MORE: “Our goal with this lab is to build a testing process to achieve standardization and systematization — from cell screening to tissue analysis and in vivo testing,” said Ma Guanghui, Director of the National Key Laboratory of Biochemical Engineering. “This facility is equipped with advanced laboratory technologies and services from PerkinElmer so that research institutions and companies can enjoy one-stop professional testing and analysis.”
“Innovating is the basis for development, and our offerings will play an important role toward leading to new breakthroughs,” said Yan Jiemin, Life Science Sales Director, Discovery & Analytical Solutions, China, PerkinElmer.
PerkinElmer and the State Key Laboratory of Biochemical Engineering also announced the formation of the Translational Medical Engineering Committee at the event.
PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
# # #